Investing Profile

Michael Rome


Managing Director & Co-Head of Therapeutics Investing at Foresite Capital Angeles, California
Photo of Michael Rome, Managing Director at Foresite Capital

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →
UCLA Network
California Institute of Technology Network
Foresite Capital Managing Director
$100K - $5.0M
CompanyStageDateRound SizeTotal Raised
Remix Therapeutics
Series BMay 2022$70M
Series ADec 2020$65M
Co-investors: Leon Chen (The Column Group), Kevin Bitterman (Atlas Venture), Kristina Burow (ARCH Venture Partners)
Series BAug 2021$50M
Co-investors: Carl Gordon (OrbiMed), Jim Tananbaum (Foresite Capital)
Series AMay 2021$70M
Co-investors: Jim Tananbaum (Foresite Capital), Vikram Bajaj (Foresite Capital)
Theseus Pharmaceuticals
Series BApr 2021$100M
Co-investors: Carl Gordon (OrbiMed)
Nurix Therapeutics
Private Equity RoundMar 2020$120M
Co-investors: David Goeddel (The Column Group)
Kinnate Biopharma
Series BDec 2019$75M
Co-investors: Carl Gordon (OrbiMed), Peter Kolchinsky (RA Capital), Brett Zbar (Foresite Capital)
Senior Analyst Foresite Capital ManagementPresent
Analyst DAFNA Capital Management, LLCPresent
Scientist and Senior Scientist Vault PharmaPresent
Graduate Researcher in Biochemistry CaltechPresent
Research Associate in Microbiology UCLAPresent
Lab Assistant and Researcher UCLAPresent
Physical Sciences Tutor Los Angeles Valley CollegePresent
Office Assistant Impact Program for Prostate Cancer TreatmentPresent
California Institute of Technology Doctor of Philosophy (Ph.D.) Biochemistry, Biophysics and Molecular Biology
UCLA BS Molecular, Cellular and Developmental Biology